Reacción a "Weight loss alone does not explain the lower incidence of heart disease in people taking semaglutide"

The study is of very high quality and its conclusions are clear: the observed benefits of semaglutide in relation to serious cardiovascular problems cannot be explained solely by the improvements seen in the main risk factors identified and assessed in this study.

In the SELECT trial, treatment with semaglutide was associated, compared with placebo, with improvements in various risk factors or markers, such as body weight, waist circumference, glycated haemoglobin, C-reactive protein, blood pressure and certain indicators of kidney function. However, the most interesting finding is that the analyses carried out did not allow the reduction in serious cardiovascular events to be attributed with certainty to the combination of these improvements. Weight loss appears to contribute to this benefit, but would only account for part of it.

The study highlights that we still do not understand a significant proportion of the mechanisms responsible for semaglutide’s cardioprotective effect. The parameters analysed primarily relate to well-known risk factors and biomarkers; therefore, further mechanistic research will be necessary to identify other possible mediators of its cardiovascular effects.

As for the implications of the study, probably the most relevant is that we must move beyond interpreting semaglutide simply as a weight-loss drug. Weight loss is undoubtedly one of its important effects, but it does not appear to explain the observed cardiovascular protection on its own. Understanding the additional mechanisms involved will allow us to better interpret its effects and, eventually, define more precisely which patients may benefit from them.